Boots announces online medical cannabis prescribing service in UK
The pharmacy chain’s SureLeaf service will assess eligible adults aged 25 and over, with specialist reviews required before treatment can begin.
By Luca Fernandez ·

Boots has announced plans to prescribe medical cannabis through an online service, becoming the first UK high street pharmacy to do so. The service, called SureLeaf, will be available to people in the UK aged 25 and over with eligible conditions, including chronic pain, anxiety and insomnia.
Patients seeking treatment will begin with an online assessment, which a clinical team will review to determine their suitability. Those progressing through the process will then be invited to a video appointment with a consultant. Boots said patients must have already tried conventional treatments unsuccessfully before medical cannabis can be considered.
A prescription will require a further independent review by a multidisciplinary clinical team, including a second consultant, before treatment starts. Patients receiving treatment will also undergo regular reviews. Alongside the launch, Boots is working with the University of Nottingham on a research programme examining patient outcomes, prescribing practices and experiences of treatment for chronic pain.
Jamie Kerruish, Boots’ chief healthcare officer, said ongoing pain affects millions of people and that conventional treatments do not always offer sufficient symptom relief. He said this can disrupt work, sleep, family time and other activities. The service’s aim, he said, was to help people explore appropriate treatment options that might improve their ability to manage symptoms and their quality of life.
Dr David Gwynne, medical director of Boots’ online service, stressed that medical cannabis would not be suitable for every patient and that prescribing required careful individual decisions. He said SureLeaf had been developed with clinical safeguards and specialist oversight throughout the process, from the initial assessment to monitoring and reviews after treatment begins.
Cannabis-derived medicines became legal to prescribe in 2018, following the seizure at airport customs of cannabis oil from the mother of a young boy from Northern Ireland who had severe epilepsy. Private clinics have prescribed these medicines for years. NHS access is limited to people with rare forms of epilepsy, certain chemotherapy side-effects or particular symptoms of multiple sclerosis. Private clinics also prescribe them for chronic pain and a range of psychiatric and neurological conditions.
Despite hopes for cannabis to transform some areas of medicine, research findings vary by condition. This year, researchers from universities in Sydney, Brisbane, Melbourne and Bath found very little evidence that cannabis effectively treated anxiety, anorexia nervosa, psychotic disorders, post-traumatic stress disorder or opioid use disorder. They did find some evidence that medical cannabis products could reduce cannabis dependence, ease Tourette syndrome symptoms and improve sleep for people with insomnia.






